The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants

Kristian W. Pajtler, Stephen C. Mack, Vijay Ramaswamy, Christian A. Smith, Hendrik Witt, Amy Smith, Jordan R. Hansford, Katja Von Hoff, Karen D. Wright, Eugene Hwang, D. Frappaz, Yonehiro Kanemura, Maura Massimino, Cecile Faure-Conter, Piergiorgio Modena, Uri Tabori, Katherine E. Warren, Eric C. Holland, Koichi Ichimura, Felice GiangasperoDavid Castel, Andreas von Deimling, Marcel Kool, Peter B. Dirks, Richard G. Grundy, Nicholas K. Foreman, Amar Gajjar, Andrey Korshunov, Jonathan L. Finlay, Richard J. Gilbertson, David W. Ellison, Kenneth D. Aldape, Thomas E. Merchant, Eric Bouffet, Stefan M. Pfister, M. Taylor

Research output: Contribution to journalArticle

Abstract

Multiple independent genomic profiling efforts have recently identified clinically and molecularly distinct subgroups of ependymoma arising from all three anatomic compartments of the central nervous system (supratentorial brain, posterior fossa, and spinal cord). These advances motivated a consensus meeting to discuss: (1) the utility of current histologic grading criteria, (2) the integration of molecular-based stratification schemes in future clinical trials for patients with ependymoma and (3) current therapy in the context of molecular subgroups. Discussion at the meeting generated a series of consensus statements and recommendations from the attendees, which comment on the prognostic evaluation and treatment decisions of patients with intracranial ependymoma (WHO Grade II/III) based on the knowledge of its molecular subgroups. The major consensus among attendees was reached that treatment decisions for ependymoma (outside of clinical trials) should not be based on grading (II vs III). Supratentorial and posterior fossa ependymomas are distinct diseases, although the impact on therapy is still evolving. Molecular subgrouping should be part of all clinical trials henceforth.

Original languageEnglish
Pages (from-to)1-8
Number of pages8
JournalActa Neuropathologica
DOIs
Publication statusAccepted/In press - Nov 17 2016

Fingerprint

Ependymoma
Clinical Trials
Therapeutics
Spinal Cord
Central Nervous System
Brain

Keywords

  • Ependymoma
  • Posterior fossa
  • RELA
  • Subgroups
  • Treatment
  • Trial
  • YAP1

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Clinical Neurology
  • Cellular and Molecular Neuroscience

Cite this

Pajtler, K. W., Mack, S. C., Ramaswamy, V., Smith, C. A., Witt, H., Smith, A., ... Taylor, M. (Accepted/In press). The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants. Acta Neuropathologica, 1-8. https://doi.org/10.1007/s00401-016-1643-0

The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants. / Pajtler, Kristian W.; Mack, Stephen C.; Ramaswamy, Vijay; Smith, Christian A.; Witt, Hendrik; Smith, Amy; Hansford, Jordan R.; Von Hoff, Katja; Wright, Karen D.; Hwang, Eugene; Frappaz, D.; Kanemura, Yonehiro; Massimino, Maura; Faure-Conter, Cecile; Modena, Piergiorgio; Tabori, Uri; Warren, Katherine E.; Holland, Eric C.; Ichimura, Koichi; Giangaspero, Felice; Castel, David; von Deimling, Andreas; Kool, Marcel; Dirks, Peter B.; Grundy, Richard G.; Foreman, Nicholas K.; Gajjar, Amar; Korshunov, Andrey; Finlay, Jonathan L.; Gilbertson, Richard J.; Ellison, David W.; Aldape, Kenneth D.; Merchant, Thomas E.; Bouffet, Eric; Pfister, Stefan M.; Taylor, M.

In: Acta Neuropathologica, 17.11.2016, p. 1-8.

Research output: Contribution to journalArticle

Pajtler, KW, Mack, SC, Ramaswamy, V, Smith, CA, Witt, H, Smith, A, Hansford, JR, Von Hoff, K, Wright, KD, Hwang, E, Frappaz, D, Kanemura, Y, Massimino, M, Faure-Conter, C, Modena, P, Tabori, U, Warren, KE, Holland, EC, Ichimura, K, Giangaspero, F, Castel, D, von Deimling, A, Kool, M, Dirks, PB, Grundy, RG, Foreman, NK, Gajjar, A, Korshunov, A, Finlay, JL, Gilbertson, RJ, Ellison, DW, Aldape, KD, Merchant, TE, Bouffet, E, Pfister, SM & Taylor, M 2016, 'The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants', Acta Neuropathologica, pp. 1-8. https://doi.org/10.1007/s00401-016-1643-0
Pajtler, Kristian W. ; Mack, Stephen C. ; Ramaswamy, Vijay ; Smith, Christian A. ; Witt, Hendrik ; Smith, Amy ; Hansford, Jordan R. ; Von Hoff, Katja ; Wright, Karen D. ; Hwang, Eugene ; Frappaz, D. ; Kanemura, Yonehiro ; Massimino, Maura ; Faure-Conter, Cecile ; Modena, Piergiorgio ; Tabori, Uri ; Warren, Katherine E. ; Holland, Eric C. ; Ichimura, Koichi ; Giangaspero, Felice ; Castel, David ; von Deimling, Andreas ; Kool, Marcel ; Dirks, Peter B. ; Grundy, Richard G. ; Foreman, Nicholas K. ; Gajjar, Amar ; Korshunov, Andrey ; Finlay, Jonathan L. ; Gilbertson, Richard J. ; Ellison, David W. ; Aldape, Kenneth D. ; Merchant, Thomas E. ; Bouffet, Eric ; Pfister, Stefan M. ; Taylor, M. / The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants. In: Acta Neuropathologica. 2016 ; pp. 1-8.
@article{2be19bf6ee064e84a121a6c1b2ce8b8b,
title = "The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants",
abstract = "Multiple independent genomic profiling efforts have recently identified clinically and molecularly distinct subgroups of ependymoma arising from all three anatomic compartments of the central nervous system (supratentorial brain, posterior fossa, and spinal cord). These advances motivated a consensus meeting to discuss: (1) the utility of current histologic grading criteria, (2) the integration of molecular-based stratification schemes in future clinical trials for patients with ependymoma and (3) current therapy in the context of molecular subgroups. Discussion at the meeting generated a series of consensus statements and recommendations from the attendees, which comment on the prognostic evaluation and treatment decisions of patients with intracranial ependymoma (WHO Grade II/III) based on the knowledge of its molecular subgroups. The major consensus among attendees was reached that treatment decisions for ependymoma (outside of clinical trials) should not be based on grading (II vs III). Supratentorial and posterior fossa ependymomas are distinct diseases, although the impact on therapy is still evolving. Molecular subgrouping should be part of all clinical trials henceforth.",
keywords = "Ependymoma, Posterior fossa, RELA, Subgroups, Treatment, Trial, YAP1",
author = "Pajtler, {Kristian W.} and Mack, {Stephen C.} and Vijay Ramaswamy and Smith, {Christian A.} and Hendrik Witt and Amy Smith and Hansford, {Jordan R.} and {Von Hoff}, Katja and Wright, {Karen D.} and Eugene Hwang and D. Frappaz and Yonehiro Kanemura and Maura Massimino and Cecile Faure-Conter and Piergiorgio Modena and Uri Tabori and Warren, {Katherine E.} and Holland, {Eric C.} and Koichi Ichimura and Felice Giangaspero and David Castel and {von Deimling}, Andreas and Marcel Kool and Dirks, {Peter B.} and Grundy, {Richard G.} and Foreman, {Nicholas K.} and Amar Gajjar and Andrey Korshunov and Finlay, {Jonathan L.} and Gilbertson, {Richard J.} and Ellison, {David W.} and Aldape, {Kenneth D.} and Merchant, {Thomas E.} and Eric Bouffet and Pfister, {Stefan M.} and M. Taylor",
year = "2016",
month = "11",
day = "17",
doi = "10.1007/s00401-016-1643-0",
language = "English",
pages = "1--8",
journal = "Acta Neuropathologica",
issn = "0001-6322",
publisher = "Springer Verlag",

}

TY - JOUR

T1 - The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants

AU - Pajtler, Kristian W.

AU - Mack, Stephen C.

AU - Ramaswamy, Vijay

AU - Smith, Christian A.

AU - Witt, Hendrik

AU - Smith, Amy

AU - Hansford, Jordan R.

AU - Von Hoff, Katja

AU - Wright, Karen D.

AU - Hwang, Eugene

AU - Frappaz, D.

AU - Kanemura, Yonehiro

AU - Massimino, Maura

AU - Faure-Conter, Cecile

AU - Modena, Piergiorgio

AU - Tabori, Uri

AU - Warren, Katherine E.

AU - Holland, Eric C.

AU - Ichimura, Koichi

AU - Giangaspero, Felice

AU - Castel, David

AU - von Deimling, Andreas

AU - Kool, Marcel

AU - Dirks, Peter B.

AU - Grundy, Richard G.

AU - Foreman, Nicholas K.

AU - Gajjar, Amar

AU - Korshunov, Andrey

AU - Finlay, Jonathan L.

AU - Gilbertson, Richard J.

AU - Ellison, David W.

AU - Aldape, Kenneth D.

AU - Merchant, Thomas E.

AU - Bouffet, Eric

AU - Pfister, Stefan M.

AU - Taylor, M.

PY - 2016/11/17

Y1 - 2016/11/17

N2 - Multiple independent genomic profiling efforts have recently identified clinically and molecularly distinct subgroups of ependymoma arising from all three anatomic compartments of the central nervous system (supratentorial brain, posterior fossa, and spinal cord). These advances motivated a consensus meeting to discuss: (1) the utility of current histologic grading criteria, (2) the integration of molecular-based stratification schemes in future clinical trials for patients with ependymoma and (3) current therapy in the context of molecular subgroups. Discussion at the meeting generated a series of consensus statements and recommendations from the attendees, which comment on the prognostic evaluation and treatment decisions of patients with intracranial ependymoma (WHO Grade II/III) based on the knowledge of its molecular subgroups. The major consensus among attendees was reached that treatment decisions for ependymoma (outside of clinical trials) should not be based on grading (II vs III). Supratentorial and posterior fossa ependymomas are distinct diseases, although the impact on therapy is still evolving. Molecular subgrouping should be part of all clinical trials henceforth.

AB - Multiple independent genomic profiling efforts have recently identified clinically and molecularly distinct subgroups of ependymoma arising from all three anatomic compartments of the central nervous system (supratentorial brain, posterior fossa, and spinal cord). These advances motivated a consensus meeting to discuss: (1) the utility of current histologic grading criteria, (2) the integration of molecular-based stratification schemes in future clinical trials for patients with ependymoma and (3) current therapy in the context of molecular subgroups. Discussion at the meeting generated a series of consensus statements and recommendations from the attendees, which comment on the prognostic evaluation and treatment decisions of patients with intracranial ependymoma (WHO Grade II/III) based on the knowledge of its molecular subgroups. The major consensus among attendees was reached that treatment decisions for ependymoma (outside of clinical trials) should not be based on grading (II vs III). Supratentorial and posterior fossa ependymomas are distinct diseases, although the impact on therapy is still evolving. Molecular subgrouping should be part of all clinical trials henceforth.

KW - Ependymoma

KW - Posterior fossa

KW - RELA

KW - Subgroups

KW - Treatment

KW - Trial

KW - YAP1

UR - http://www.scopus.com/inward/record.url?scp=84995807087&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995807087&partnerID=8YFLogxK

U2 - 10.1007/s00401-016-1643-0

DO - 10.1007/s00401-016-1643-0

M3 - Article

SP - 1

EP - 8

JO - Acta Neuropathologica

JF - Acta Neuropathologica

SN - 0001-6322

ER -